Jeff Elliott: There was two more parts to the question. This is Jeff. There was one on re-screens. The headwind that I’ve talked about before was it’s about 50 million for the year. If you think about that hitting second quarter, third quarter and fourth quarter. Third quarter gets a bit more than a third of that. And second and fourth get a bit less than a third, but it’s fairly evenly spread. And the team did a very nice job working to offset, at least partially offset the headwind during the quarter. Yeah, so you also understand that the care gap business, but this is a really small part of it. I had previously guided to somewhere just over 10 million in the whole second half for this business. It was more weighted towards Q4.
That was the previous guidance. And what we found out during the quarter is that a bit more of that fell into Q3 than I previously expected. All told, it’s a pretty small part of the business today. What really drove the quarter was the core underlying business that will sustain. It is a very durable leg of growth for us.
Operator: Thank you. We’ll go next now to Alex Nowak at Craig-Hallum.
Albert Hu: Hi. Good afternoon, everyone. This is Albert Hu on for Alex. So after the FDA approval for the next gen Cologuard, can you give us some rollout plans to physicians across the U.S. that you guys have as of right now? And we were also in the lab in June and what’s the latest plan to build the next gen Cologuard in the vacant footprint for the lab? And how do you guys plan to convert the existing process over to the next gen without running into any backlog issues?
Everett Cunningham: Let me take the second part of that and hand the first part in terms of promoting and educating next gen Cologuard to primary care docs. In terms of lab capacity during that tour you saw the additional 200,000 square feet of space that we have that is prepared for current and future product growth. So we have ample capacity at the two labs that we have today, coupled with automation that constantly is being implemented to increase to a capacity easily of 10 million tests per year. And switching over to Cologuard 2.0 we have plenty of space, physical space here in Madison, Wisconsin to be able to meet that need. We have a very thoughtful plan from top to bottom about how that is going to happen and our team over the last 10 years I’m very proud to say our operations team, our lab team have never missed.
We’ve never had a day, a week, a month that we couldn’t generate Cologuard results. This is an amazing team of professionals, automation experts, scientists, laboratorians who will make this a smooth changeover.
Kevin Conroy: In terms of getting Cologuard ready for the next kind of year, what we’re going to do I look at it two ways. First of all, we have a year to get ready, but the most important thing that we can do commercially is sell Cologuard and focus on making sure that we get those providers that are writing it to write more, those providers that are not writing it to get to start writing Cologuard. What we like about the next generation Cologuard is there’s 30% fewer false positives. And we know those physicians for whatever reason is a major roadblock for them. They stay away from Cologuard because of the false positives. We know exactly who those physicians are and that will be our first kind of low hanging fruit, is to go to those physicians and talk about the next generation Cologuard and get them excited.
What I like about the next generation Cologuard is internally our entire company is excited about this. And so we’re going to use that excitement, that excitement in the field to increase again the people that are writing Cologuard.
Operator: Thank you. And that does conclude our question-and-answer session for this afternoon, ladies and gentlemen and it will bring us to the close of the call. We’d like to thank you all so much for joining the Exact Sciences Third Quarter 2023 Earnings Call. Again, thank you for joining and have a great afternoon. Goodbye.
